Dutch health package excludes two medicines after price talks fail

The Dutch government will not reimburse two medicines through the basic health insurance package for now, after price talks with their manufacturers failed to produce what it considers an acceptable deal. The decision affects Skyclarys for the rare condition Friedreich’s ataxia and Enhertu for advanced or metastatic stomach cancer.[1]

The Dutch National Health Care Institute advised the health minister that both medicines offer benefits but cost too much. It recommended an 84% price cut for Skyclarys, whose published list price is more than €245,000 per patient a year. The medicine can slow the progression of Friedreich’s ataxia, but not stop it, the government said.[1]

For Enhertu’s stomach-cancer use, the institute recommended a price reduction of more than 62%. The government said the treatment extends average survival by just over four months compared with chemotherapy.[1]

Health Minister Sophie Hermans said she had tried to reach an agreement with the manufacturers, but could not accept new medicines at any price. She said public healthcare funds had to be used fairly and effectively for all patients.[1]

The minister said reimbursement could still be considered if suppliers agree to an acceptable price or new evidence prompts a revised recommendation. Enhertu remains covered for HER2-positive breast cancer, under a contract due for renewal after 1 January 2028.[1]